Ajay Tiku, Region Medical Head, Innovative Medicines, Asia Pacific, Middle East and Africa (APMA) at Novartis, recently shared his perspective regarding pharmaceutical industry initiatives to prevent cardiovascular disease (CVD) in an engaging interview with BioSpectrum. The article offered valuable insights into the state of CVD in the Asia Pacific, Middle East and Africa (APMA) region, highlighting the work Novartis is undertaking there with the healthcare ecosystem.
Ajay’s conversation continues recent efforts by Novartis to tackle the healthcare challenges posed by CVD, as part of the Unblocked Movement initiative. The Unblocked Movement is a co-created initiative with partners and supported by Novartis to bring patients, their loved ones, healthcare professionals and healthcare systems together in a shared mission to “unblock” barriers to heart health.
Learn more about the partnerships that Novartis has in the region to address cardiovascular disease together, here.